RESUMEN
The preclinical pharmacology and pharmacokinetic properties of (2R)-6-methoxy-8-(4-methylpiperazin-1-yl)-N-(4-morpholin-4-ylphenyl)chromane-2-carboxamide (AZD3783), a potent 5-hydroxytryptamine 1B (5-HT(1B)) receptor antagonist, were characterized as part of translational pharmacokinetic/pharmacodynamic hypothesis testing in human clinical trials. The affinity of AZD3783 to the 5-HT(1B) receptor was measured in vitro by using membrane preparations containing recombinant human or guinea pig 5-HT(1B) receptors and in native guinea pig brain tissue. In vivo antagonist potency of AZD3783 for the 5HT(1B) receptor was investigated by measuring the blockade of 5-HT(1B) agonist-induced guinea pig hypothermia. The anxiolytic-like potency was assessed using the suppression of separation-induced vocalization in guinea pig pups. The affinity of AZD3783 for human and guinea pig 5-HT(1B) receptor (K(i), 12.5 and 11.1 nM, respectively) was similar to unbound plasma EC(50) values for guinea pig receptor occupancy (11 nM) and reduction of agonist-induced hypothermia (18 nM) in guinea pig. Active doses of AZD3783 in the hypothermia assay were similar to doses that reduced separation-induced vocalization in guinea pig pups. AZD3783 demonstrated favorable pharmacokinetic properties. The predicted pharmacokinetic parameters (total plasma clearance, 6.5 ml/min/kg; steady-state volume of distribution, 6.4 l/kg) were within 2-fold of the values observed in healthy male volunteers after a single 20-mg oral dose. This investigation presents a direct link between AZD3783 in vitro affinity and in vivo receptor occupancy to preclinical disease model efficacy. Together with predicted human pharmacokinetic properties, we have provided a model for the quantitative translational pharmacology of AZD3783 that increases confidence in the optimal human receptor occupancy required for antidepressant and anxiolytic effects in patients.
Asunto(s)
Benzopiranos/farmacología , Benzopiranos/farmacocinética , Morfolinas/farmacología , Morfolinas/farmacocinética , Unión Proteica/efectos de los fármacos , Receptor de Serotonina 5-HT1B/metabolismo , Antagonistas del Receptor de Serotonina 5-HT1/farmacología , Antagonistas del Receptor de Serotonina 5-HT1/farmacocinética , Subfamilia B de Transportador de Casetes de Unión a ATP/análisis , Animales , Ansiolíticos/sangre , Ansiolíticos/química , Ansiolíticos/farmacocinética , Ansiolíticos/farmacología , Conducta Animal/efectos de los fármacos , Benzopiranos/sangre , Benzopiranos/química , Modelos Animales de Enfermedad , Perros , Método Doble Ciego , Cobayas , Hepatocitos/efectos de los fármacos , Humanos , Hipotermia Inducida , Macaca fascicularis , Masculino , Microsomas Hepáticos/efectos de los fármacos , Terapia Molecular Dirigida , Morfolinas/sangre , Morfolinas/química , Ensayo de Unión Radioligante , Ratas Sprague-Dawley , Antagonistas del Receptor de Serotonina 5-HT1/sangre , Antagonistas del Receptor de Serotonina 5-HT1/química , Agonistas de Receptores de Serotonina/efectos adversos , Agonistas de Receptores de Serotonina/farmacología , Investigación Biomédica TraslacionalRESUMEN
We describe herein the discovery of novel, de novo designed, 5-HT(1B) receptor antagonists that lack a basic moiety and that provide improved hERG and in vitro phospholipidosis profiles. We used a known 5-HT(1B) antagonist template as our starting point and focused on replacing the piperazine moiety. Pyrazole-based ideas were designed and synthesized among a small library of piperazine replacements. To our knowledge, these are the first potent, nonbasic, functionally active antagonists of the 5-HT(1B) receptor.
Asunto(s)
Pirazoles/síntesis química , Antagonistas del Receptor de Serotonina 5-HT1 , Animales , Unión Competitiva , Células CHO , Técnicas Químicas Combinatorias , Cricetinae , Cricetulus , Diseño de Fármacos , Agonismo Parcial de Drogas , Canal de Potasio ERG1 , Canales de Potasio Éter-A-Go-Go/metabolismo , Cobayas , Humanos , Hipotermia/tratamiento farmacológico , Lipidosis/inducido químicamente , Lipidosis/metabolismo , Fosfolípidos/metabolismo , Piperazinas/efectos adversos , Piperazinas/síntesis química , Piperazinas/farmacología , Pirazoles/efectos adversos , Pirazoles/farmacología , Ensayo de Unión Radioligante , Agonistas del Receptor de Serotonina 5-HT1 , Relación Estructura-ActividadRESUMEN
Cerebral deposition of amyloid beta-protein (A beta) is believed to play a key role in the pathogenesis of Alzheimer's disease. Because A beta is produced from the processing of amyloid beta-protein precursor (APP) by beta- and gamma-secretases, these enzymes are considered important therapeutic targets for identification of drugs to treat Alzheimer's disease. Unlike beta-secretase, which is a monomeric aspartyl protease, gamma-secretase activity resides as part of a membrane-bound, high molecular weight, macromolecular complex. Pepstatin and L685458 are among several structural classes of gamma-secretase inhibitors identified so far. These compounds possess a hydroxyethylene dipeptide isostere of aspartyl protease transition state analogs, suggesting gamma-secretase may be an aspartyl protease. However, the mechanism of inhibition of gamma-secretase by pepstatin and L685458 has not been elucidated. In this study, we report that pepstatin A methylester and L685458 unexpectedly displayed linear non-competitive inhibition of gamma-secretase. Sulfonamides and benzodiazepines, which do not resemble transition state analogs of aspartyl proteases, also displayed potent, non-competitive inhibition of gamma-secretase. Models to rationalize how transition state analogs inhibit their targets by non-competitive inhibition are discussed.